Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular biomarkers of thrombosis in myeloproliferative neoplasms.

Thrombosis research - 1 Apr 2016

Barbui Tiziano, Falanga Anna

Abstract excerpt

JAK2 mutations define polycythemia vera (PV), CALR and MPL mutations are specific to JAK2 unmutated essential thrombocythemia (ET) and primary myelofibrosis (PMF). We overviewed the current knowledge on the relationship between these phenotypic driver mutations and thrombotic complications that are major cause of morbidity and mortality in patients with myeloproliferative neoplasms (MPN) particularly PV and ET....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to CALR gene
Share to MPL gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Mutation

Share to Myeloproliferative Disorders

Share to Receptors, Thrombopoietin

Share to Thrombosis

Source

Identifiers

PMID: 27067982
DOI: 10.1016/S0049-3848(16)30102-5

Genes

JAK2
MPL
CALR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular biomarkers of thrombosis in myeloproliferative neoplasms.PMID 27067982Read ↗

JAK2 mutation-related disease and thrombosis.Semantic proximity Read ↗

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.Semantic proximity Read ↗

Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision OncologySemantic proximity Read ↗

It is time to change thrombosis risk assessment for PV and ET?Semantic proximity Read ↗

Thrombocytosis and thrombosis.Semantic proximity Read ↗

Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.Semantic proximity Read ↗

Clinical insights into the origins of thrombosis in myeloproliferative neoplasms.Semantic proximity Read ↗

Thrombosis-Driven Disease Progression in JAK2-Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk-Based Management.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

JAK2 mutation and thrombosis in the myeloproliferative neoplasms.Semantic proximity Read ↗

The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective.Semantic proximity Read ↗

Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.